Dennis,
Exactly correct. Generally, rolling out the data for the first time isn't really offering much news if the description of the results of the data initally given truly were accurate, which it appears to have been...we'll find out for sure soon enough. This kind of presentation necessitates a release, even though of course nobody would expect that it would do anything for significant price movement other than maybe some brief support. Looks like in a rockier market the price could give back a bit more in the short haul, although the panel meeting may not be that far away.....tentative fda plastics panel meetings are in late jan and again in april I think, but there has been no decision as to the agendas specifically at this point...I would expect that ATIS will put out a release as soon as they know...has to by 15 days before, as Rick has told us before, so we're not looking at that far away if late january turns out to be the date. FWIW, ATIS says all of the info is in, and was totally available and submitted before the end of october.
Interesting info potentially for those interested, although off-topic, about a major pharm. player...LLY.......tomorrow am they have their new osteoporosis med, roloxifene, in front of the endo. panel, so could make for an interesting day for them depending on the recommendations, especially for those who play options. I saw that Novartis had their prandin for diabetics recommended today by that panel.
Take care all,
Marshall |
